

IMAGION BIOSYSTEMS LIMITED

ASX: IBX

14 July 2023

Non-renounceable Entitlement Offer Shortfall

MELBOURNE — **Imagion Biosystems Limited (ASX: IBX)**, a company dedicated to improving healthcare through the earlier detection of cancer, refers to its announcements titled 'Non-renounceable Entitlement Offer' dated 7 March 2023 and 'Results of Non-renounceable Entitlement Offer' dated 19 April 2023 in relation to the pro rata non-renounceable entitlement offer to existing eligible shareholders to raise up to \$2.4 million through the offer of one (1) new fully paid ordinary shares in the Company for every eight (8) shares held by eligible shareholders registered at 10 March 2023 at an issue price of \$0.017 per share.

Capitalised terms used in this announcement but not defined have the meaning given to them in the Offer Document released to ASX on 7 March 2023, unless the context requires otherwise.

The Company today announces that it has placed the total Shortfall, of approximately \$1.97 million and represented by 115,878,572 Shares, in accordance with section 2.10 of the Offer Booklet. The Shortfall Shares have today been allotted with a corresponding Appendix 2A to be released to the ASX shortly after this announcement.

— ENDS —

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

Imagion Biosystems Interactive Investor Hub

Engage with us directly by asking questions, watching video summaries, and seeing what other shareholders have to say about this and past announcements at our Investor Hub:

<https://investorhub.imaginationbiosystems.com/>

Imagion Biosystems Limited

ASX:IBX ACN 616 305 027

Level 25, 525 Collins Street, Melbourne VIC 3000

www.imaginationbiosystems.com | investor@imaginationbio.com



Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagination Biosystems Limited.

Australian Media & Investor Relations:

Hannah Howlett, WE Communications

We-AUImagionBiosystems@we-worldwide.com

+61 450 648 064

U.S. Media Contact

Casie Ost

casie.ost@imaginationbio.com

+1-619-693-4428

